Tax withholding trims Protara (TARA) VP Hannah Fry’s stock stake

Rhea-AI Filing Summary

Protara Therapeutics VP and Controller Hannah Fry reported a routine share withholding related to equity compensation. On January 20, 2026, the company withheld 2,132 shares of common stock at a value of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards originally granted on January 19, 2023 and January 19, 2024. After this tax-related transaction, Fry beneficially owned 44,180 shares of Protara Therapeutics common stock in direct ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fry Hannah

Role VP, Controller

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,132	$5.60	$12K

Holdings After Transaction: Common Stock — 44,180 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fry Hannah

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Controller

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		F		2,132(1)	D	$5.6	44,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024.

Remarks:

	/s/ Hannah Fry	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) report for Hannah Fry?

Protara Therapeutics reported that VP and Controller Hannah Fry had 2,132 shares of common stock withheld on January 20, 2026 to satisfy income tax obligations tied to vesting restricted stock units.

What does the Form 4 transaction code "F" mean in the Protara (TARA) filing?

The transaction code "F" in Hannah Fry’s Form 4 indicates shares were withheld by the issuer to pay taxes owed upon the vesting of equity awards, rather than a discretionary market sale.

How many Protara Therapeutics shares does Hannah Fry own after this transaction?

Following the tax withholding of 2,132 shares, Hannah Fry beneficially owned 44,180 shares of Protara Therapeutics common stock in direct ownership.

Was this Protara (TARA) insider transaction an open market sale?

No. According to the footnote, the 2,132 shares were withheld by Protara Therapeutics to cover income tax obligations from vesting restricted stock unit awards, not sold in an open market transaction.

What awards caused the share withholding for the Protara VP on this Form 4?

The share withholding related to the vesting of Restricted Stock Unit Awards granted to Hannah Fry on January 19, 2023 and January 19, 2024.

What is Hannah Fry’s role at Protara Therapeutics (TARA)?

Hannah Fry is listed as an officer of Protara Therapeutics with the title VP, Controller in the Form 4 filing.